Navigation Links
Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
Date:5/14/2013

comprises a group of individuals who have made significant contributions to the advancement of medical science, biotech entrepreneurship and the development of drugs serving unmet medical needs," said Sir Michael.  "ITI has set itself on a course to develop outstanding new pharmaceuticals to treat CNS diseases, surely an ambitious task, but one in which I am pleased to join and help."

ABOUT ITI-007

ITI-007 is the Company's first-in-class antipsychotic with a unique mechanism of action.  ITI-007 combines potent 5-HT2A receptor antagonism with dopamine receptor phosphoprotein modulation (DPPM) and serotonin reuptake inhibition for the treatment of acute and residual schizophrenia.  At dopamine D2 receptors, ITI-007 has dual properties acting as a post-synaptic antagonist and as a pre-synaptic partial agonist.  ITI-007 also stimulates phosphorylation of glutamatergic NMDA NR2B receptors in a mesolimbic specific manner.  This regional selectivity in brain areas thought to mediate the efficacy of antipsychotic drugs together with serotonergic, glutamatergic, and dopaminergic interactions is expected to result in superior antipsychotic efficacy for positive, negative, affective and cognitive symptoms associated with schizophrenia.  The serotonin reuptake inhibition allows for additional antidepressant efficacy for the treatment of schizoaffective disorder, co-morbid depression, and/or as a stand-alone treatment for major depressive disorder (MDD).  ITI-007 is currently in a Phase II clinical trial in schizophrenia.  We believe ITI-007 will be useful for the treatment of behavioral disturbances in dementia, autism and other CNS diseases and well as in bipolar disorder and other psychiatric and neurodegenerative disorders.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of t
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
5. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
9. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the ... President of Managed Care. In this role, Damm will ... the nation’s leading specialty pharmacies. , Damm, who is ... specialty pharmacy and biotech experience to his new position ... Pharmaceuticals, and Pfizer. Prior to working in Healthcare Damm ...
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Mature Biotech Outlook 2015: New Therapy Ventures Pave the ... All biotech companies - Gilead (GILD), Amgen ... year, have given a positive return and hence increased ... able to select therapy/niche indication where the high treatment ...
(Date:3/4/2015)... 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the: , 3.75% Convertible Senior Notes due May ... stock per $1,000 principal amount or approximately $5.72 per share, ... the note is adjusted in connection with the regular quarterly ... all stockholders who own shares of PDL on March 5, 2015, ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... Jim Calhoun Credits Early Diagnosis with Saving his ... AdvaMed 2007:,The MedTech Conference will highlight how everyday patients ... well as speakers on the,diversity and strength of the ... Oct. 1 through Oct. 3., Co-writing "A PASSION ...
... York, October 2 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... Annual General Meeting and Extraordinary General Meeting held,earlier today, ... The cancellation of the listing of the Company,s Ordinary ... Authority will take place at,8:00 am (London Time) on ...
... Othera Pharmaceuticals, Inc., a,specialty pharmaceuticals company focused ... inflammatory disease, has,announced the appointment of Frederick ... effective immediately. In this position, Dr. Rickles,will ... Othera,s research,and clinical development programs. "We ...
Cached Biology Technology:U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 3Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... An international team from The Australian National ... of Kiribati, the French agency CIRAD and the ... the impacts of natural and human-induced changes on ... since 1996. The work was initiated by ...
... Growth ,Kazunori Kanemaru, Yohei Okubo, Kenzo Hirose, ... explore the signaling pathway between spontaneous Ca 2+ ... growth. Their results reveal a role for the membrane-bound ... oscillations by preventing IP 3 signaling with retroviral-mediated ...
... task of getting from one place to another. Although ... geometric cues; things such as walls and corners to ... such as rats and human children are so influenced ... reliable features such as a distinctive object or colored ...
Cached Biology News:Freshwater supplies threatened in central Pacific 2News tips from the Journal of Neuroscience 2News tips from the Journal of Neuroscience 3New study examines how rearing environment can alter navigation 2
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: